Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).


Clinical Trial Description

Transplantation with G-CSF #Granulocyte colony stimulating factor #mobilized peripheral blood stem cell (PBSCT) has been a stable transplant setting with matched sibling donor transplantation. Unmanipulated haploidentical donor PBSCT (haplo-PBSCT) has been applied in patients with hematologic malignancies. In our previous cohort study, haplo-PBSCT was associated with lower incidence of severe acute GVHD and extensive chronic GVHD compared with matched sibling donor PBSCT (MSD-PBSCT). Haplo-PBSCT has the same GVHD prophylaxis regimen with MSD-PBSCT, except ATG. It suggested the potential advantage of ATG in prophylaxis of GVHD and improvement of long term quality of life of the transplant recipients, which motivate us to observe the efficacy of combined ATG regimen for GVHD prophylaxis in MSD-PBSCT. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05214066
Study type Interventional
Source Chinese PLA General Hospital
Contact Daihong Liu, Doctor
Phone +8613681171597
Email [email protected]
Status Recruiting
Phase Phase 2
Start date February 1, 2019
Completion date August 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05531266 - Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease N/A
Recruiting NCT02848105 - Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD Phase 2
Recruiting NCT03763318 - A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD Phase 1/Phase 2
Completed NCT02677181 - Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Phase 4
Completed NCT04397367 - Low Dose Ruxolitinib in Combination With Methylprednisolone Phase 1/Phase 2
Recruiting NCT03614143 - Biomarker Study for Prediction of aGVHD
Recruiting NCT04061876 - First Line Therapy for High Risk Acute GVHD Phase 2
Recruiting NCT05263999 - A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Phase 3